These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 19661401)

  • 21. Disease outbreaks: support for a cholera vaccine stockpile.
    Binagwaho A; Nyatanyi T; Nutt CT; Wagner CM
    Nature; 2012 Jul; 487(7405):39. PubMed ID: 22763542
    [No Abstract]   [Full Text] [Related]  

  • 22. The value of and challenges for cholera vaccines in Africa.
    von Seidlein L; Jiddawi M; Grais RF; Luquero F; Lucas M; Deen J
    J Infect Dis; 2013 Nov; 208 Suppl 1():S8-14. PubMed ID: 24101650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholera: an overview with reference to the Yemen epidemic.
    Rabaan AA
    Front Med; 2019 Apr; 13(2):213-228. PubMed ID: 29934743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug resistance in Vibrio cholerae.
    Anand VK; Arora S; Patwari AK; Agarwal GD; Dewan N
    Indian Pediatr; 1996 Sep; 33(9):774-7. PubMed ID: 9057408
    [No Abstract]   [Full Text] [Related]  

  • 25. Public health. Policy shifts on emergency use of cholera vaccines.
    Enserink M
    Science; 2012 Aug; 337(6096):785-6. PubMed ID: 22903987
    [No Abstract]   [Full Text] [Related]  

  • 26. Tetracycline resistant cholera in Kelantan.
    Ranjit K; Nurahan M
    Med J Malaysia; 2000 Mar; 55(1):143-5. PubMed ID: 11072502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How many cholera deaths can be averted in Haiti?
    Sack DA
    Lancet; 2011 Apr; 377(9773):1214-6. PubMed ID: 21414660
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of Vibrio cholerae vaccine in an outbreak in Guinea.
    Luquero FJ; Grout L; Ciglenecki I; Sakoba K; Traore B; Heile M; Diallo AA; Itama C; Page AL; Quilici ML; Mengel MA; Eiros JM; Serafini M; Legros D; Grais RF
    N Engl J Med; 2014 May; 370(22):2111-20. PubMed ID: 24869721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antibiotic susceptibility of Vibrio cholerae 01: evolution after prolonged curative and preventive use during the 2004 cholera epidemics in Douala (Cameroon)].
    Guévart E; Solle J; Mouangue A; Noeske J; Bita A; Fonkoua MC; Ndayo Wouafo M
    Med Mal Infect; 2006 Jun; 36(6):329-34. PubMed ID: 16757139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholera, 2007.
    Wkly Epidemiol Rec; 2008 Aug; 83(31):269-83. PubMed ID: 18668979
    [No Abstract]   [Full Text] [Related]  

  • 31. Vibrio cholerae 01 strain resistant to vibriostatic compound 0/129 isolated from cholera cases in Kilifi, Kenya.
    Khamala JK; Mwarumba S; Lewa P; Lowe B
    East Afr Med J; 2002 Oct; 79(10):560. PubMed ID: 12635766
    [No Abstract]   [Full Text] [Related]  

  • 32. Cholera vaccines: WHO position paper – August 2017.
    Wkly Epidemiol Rec; 2017 Aug; 92(34):477-98. PubMed ID: 28845659
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cholera 2].
    Bol P
    Ned Tijdschr Tandheelkd; 2000 May; 107(5):215-6. PubMed ID: 11385820
    [No Abstract]   [Full Text] [Related]  

  • 34. [Anticholera vaccines and vaccination].
    Ivanoff B; Chaignat CL
    Bull Soc Pathol Exot; 2002 Dec; 95(5):355-8. PubMed ID: 12696375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea.
    Ciglenecki I; Sakoba K; Luquero FJ; Heile M; Itama C; Mengel M; Grais RF; Verhoustraeten F; Legros D
    PLoS Med; 2013; 10(9):e1001512. PubMed ID: 24058301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of cholera vaccines and their public health implications.
    Desai SN; Clemens JD
    Curr Opin Pediatr; 2012 Feb; 24(1):85-91. PubMed ID: 22157363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cholera. Systems of international control].
    Giannico L
    Minerva Med; 1974 Sep; 65(66):3435-40. PubMed ID: 4472883
    [No Abstract]   [Full Text] [Related]  

  • 38. Cholera--the new epidemic?
    Keddy KH; Koornhof HJ
    S Afr Med J; 1998 Oct; 88(10):1313-4. PubMed ID: 9807185
    [No Abstract]   [Full Text] [Related]  

  • 39. Formulation in tablets of a cholera whole cells inactivated vaccine candidate.
    Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current problems of El Tor cholera].
    Solt K; Budai J; Vass A; Erdös L
    Orv Hetil; 1974 Mar; 115(9):488-91. PubMed ID: 4815452
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.